Established Investigator Awards
Established Investigator Awards support senior investigators conducting innovative, translational melanoma research to advance prevention, diagnosis, staging, and treatment in the near and intermediate future.
Browse similar grants
Funder: Melanoma Research Alliance
Due Dates: August 21, 2026 (Letter of intent) | December 10, 2026 (Invited full proposal)
Funding Amounts: At least $7.9 million planned across MRA’s 2026–2027 funding cycle
Summary: Supports senior investigators conducting innovative, translational melanoma research to advance prevention, diagnosis, staging, and treatment.
Key Information: Applicants must be past the initial five years of their first academic faculty appointment.
Description
The Melanoma Research Alliance (MRA) Established Investigator Awards support senior investigators with an established record of scientific productivity and accomplishment. The awards focus on innovative, translational melanoma research intended to affect prevention, diagnosis, staging, and treatment in the near and intermediate future.
The 2026–2027 Request for Proposals seeks pre-clinical, translational, and early clinical research with the potential to produce unusually high-impact, near-term advances in melanoma care. The cycle includes special Established Investigator opportunities focused on acral and uveal melanoma, as well as opportunities for applicants based in the United Kingdom and Israel. MRA accepts proposals from researchers worldwide and encourages a diverse pool of investigators.
